Brokerages Set Oculis Holding AG (NASDAQ:OCS) PT at $35.75

Shares of Oculis Holding AG (NASDAQ:OCS) have earned a consensus recommendation of “Moderate Buy” from the five brokerages that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $35.75.

OCS has been the subject of several analyst reports. HC Wainwright raised their price target on shares of Oculis from $32.00 to $33.00 and gave the stock a “buy” rating in a report on Friday, August 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Oculis in a research note on Saturday, September 27th. Needham & Company LLC started coverage on shares of Oculis in a report on Wednesday, August 27th. They issued a “buy” rating and a $36.00 target price on the stock. Finally, Wall Street Zen downgraded Oculis from a “hold” rating to a “sell” rating in a report on Sunday, September 21st.

Hedge Funds Weigh In On Oculis

Several institutional investors have recently added to or reduced their stakes in OCS. Kestra Private Wealth Services LLC bought a new position in shares of Oculis during the 1st quarter worth approximately $234,000. Bosun Asset Management LLC bought a new stake in shares of Oculis during the second quarter valued at approximately $378,000. Marshall Wace LLP acquired a new position in shares of Oculis during the second quarter worth approximately $393,000. Bank of America Corp DE lifted its holdings in shares of Oculis by 58.2% in the 4th quarter. Bank of America Corp DE now owns 28,980 shares of the company’s stock worth $493,000 after purchasing an additional 10,667 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Oculis by 27.7% in the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock worth $571,000 after purchasing an additional 6,384 shares in the last quarter. 22.30% of the stock is owned by institutional investors and hedge funds.

Oculis Stock Up 0.6%

Shares of NASDAQ:OCS opened at $17.57 on Friday. The business has a fifty day simple moving average of $17.50 and a 200 day simple moving average of $18.07. Oculis has a 12-month low of $12.48 and a 12-month high of $23.08. The firm has a market cap of $767.11 million, a P/E ratio of -6.58 and a beta of 0.29. The company has a quick ratio of 4.55, a current ratio of 4.55 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS) last issued its quarterly earnings data on Thursday, August 21st. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.06). The company had revenue of $0.25 million for the quarter, compared to the consensus estimate of $0.14 million. Oculis had a negative return on equity of 90.31% and a negative net margin of 13,958.12%. Analysts predict that Oculis will post -2.09 earnings per share for the current year.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.